Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6618392 | 1.00 | TP53 (0.56) | TP53LMNAKMT2AMEN1POLB | |
| SCHEMBL6614962 | 0.90 | — | — | |
| SCHEMBL6614967 | 0.90 | — | — | |
| SCHEMBL6616199 | 0.88 | KMT2A (0.56) | TP53LMNAKMT2AMEN1POLB | |
| SCHEMBL6616197 | 0.88 | KMT2A (0.56) | TP53LMNAKMT2AMEN1POLB | |
| SCHEMBL7558097 | 0.85 | PDE7A (0.41) | TP53LMNAKMT2AMEN1POLB | |
| SCHEMBL6618088 | 0.85 | KMT2A (0.71) | TP53LMNAKMT2AMEN1POLB | |
| SCHEMBL6618091 | 0.85 | KMT2A (0.71) | TP53LMNAKMT2AMEN1POLB | |
| SCHEMBL6615593 | 0.78 | TP53 (0.48) | TP53POLB | |
| SCHEMBL6615595 | 0.78 | TP53 (0.48) | TP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0900568-A2 | AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy | Pfizer Products Inc. (US) | 1999-03-10 | — | — | EP | claimed |
| US-20200397751-A1 | Modulation of AMPA/kainate Receptors for the Treatment of Hypoglycemia | VANDERKLISH PETER (US) | 2020-12-24 | — | — | US | disclosed |
| EP-0964860-B1 | ATROPISOMERS OF 3-HETEROARYL-4(3H)-QUINAZOLINONES FOR THE TREATMENT OF NEURODEGENERATIVE AND CNS-TRAUMA RELATED CONDITIONS | PFIZER PROD INC (US) | 2004-04-21 | — | — | EP | disclosed |
| US-6380204-B1 | ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID RECEPTOR ANTAGONIST ACTIVITY | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| US-6136812-A | Methods of administering AMPA receptor antagonists to treat dyskinesias associated with dopamine agonist therapy | PFIZER INC (US) | 2000-10-24 | — | — | US | disclosed |
| CN-1248254-A | Atropisomers of 3-heteroaryl-4(3H)-quinazolinones for treatment of neurodegenerative and CNS-trauma related conditions | PFIZER PROD INC (US) | 2000-03-22 | — | — | CN | disclosed |
| EP-0964860-A1 | ATROPISOMERS OF 3-HETEROARYL-4(3H)-QUINAZOLINONES FOR THE TREATMENT OF NEURODEGENERATIVE AND CNS-TRAUMA RELATED CONDITIONS | Pfizer Products Inc. (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0900568-A2 | AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy | Pfizer Products Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| WO-1998038187-A1 | ATROPISOMERS OF 3-HETEROARYL-4(3H)-QUINAZOLINONES FOR THE TREATMENT OF NEURODEGENERATIVE AND CNS-TRAUMA RELATED CONDITIONS | PFIZER PRODUCTS INC. (US) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397751-A1 | Modulation of AMPA/kainate Receptors for the Treatment of Hypoglycemia | GPR119, GRIK1, GRIK3 | TP53 4804/4885LMNA 4525/4885KMT2A 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.